Introduction

When a rare condition affects the nervous system, it can be overwhelming for patients and families. Erdheim-Chester disease (ECD) is one such illness; a rare form of non-Langerhans cell histiocytosis characterised by the abnormal accumulation of histiocytes (a type of immune cell) in multiple organs. In nearly half of the cases, it involves the bones, heart, lungs, and kidneys, the brain and spinal cord 

Neurological involvement in ECD is important because it often leads to significant disability and worse survival outcomes. Fortunately, modern imaging techniques and targeted therapies are improving both recognition and management of the disease. This article will guide you through what ECD is, how it affects the central nervous system (CNS), what symptoms to look out for, and how treatments are evolving.

How does ECD affect the central nervous system?

Studies show that up to 50% of patients with ECD develop CNS involvement during the course of their illness, though fewer initially present with neurological symptoms.^1,2 The disease most commonly affects the brain parenchyma, meninges, pituitary gland, and spinal cord.

On brain imaging, three main patterns of involvement have been identified:

• Tumoral pattern - mass-like lesions in the brain or meninges
• Pseudodegenerative pattern - brain atrophy or white matter changes resembling neurodegenerative disease
• Vascular pattern - narrowing of cerebral vessels or infarcts

In a multicenter MRI study of 58 patients, cortical lesions were seen in 46.6%, brainstem lesions in 29.3%, cerebellar lesions in 25.9%, and pituitary involvement in 17.2%.³

A systematic review of 40 cases found that the most frequent neurological manifestations were cranial neuropathies and ataxia, while seizures, headaches, and psychiatric symptoms were less common. Importantly, the presence of CNS disease correlated with a mortality rate approaching one-third, highlighting its seriousness.⁴

There’s more to explore

Neurological complications of ECD are complex and multifaceted. In the following sections, we will explore the clinical spectrum, the imaging patterns, their impact on prognosis, and the therapeutic strategies currently available. Understanding these details can empower both patients and clinicians to act more effectively and manage the condition earlier.

Clinical spectrum of CNS presentations

CNS involvement in ECD can manifest in many different ways, depending on which brain structures are affected.

• Cranial neuropathies: Patients may present with double vision, facial weakness, or hearing loss when cranial nerves are infiltrated^4,5
• Cerebellar signs: Ataxia (characterised by unsteady gait and poor coordination) is one of the most frequently reported symptoms, reflecting cerebellar infiltration⁴
• Cognitive and psychiatric changes: Some patients experience memory impairment, depression, or personality changes. These can be mistaken for primary psychiatric disorders unless imaging is performed²
• Seizures and headaches: Although less common, they may occur when cortical or meningeal lesions are present³
• Endocrine dysfunction: When the pituitary gland is affected, patients may develop diabetes insipidus, characterised by excessive thirst and urination⁶

Because the neurological presentation is so varied, ECD can mimic multiple other neurological diseases, from multiple sclerosis to brain tumours. This makes careful imaging and histological confirmation essential.

Imaging patterns on MRI

Magnetic Resonance Imaging (MRI)

MRI is the gold standard for evaluating CNS disease in ECD. It provides detailed soft-tissue contrast and helps to classify lesions. Three main MRI patterns are recognised:^2,3

• Tumoral pattern: Mass-like lesions, often enhancing with contrast. They may be seen in the brain parenchyma, meninges, or posterior fossa. These can mimic gliomas or meningiomas
• Pseudodegenerative pattern: White matter hyperintensities or cortical atrophy resembling demyelinating or degenerative disorders
• Vascular pattern: Stenosis or occlusion of cerebral arteries, sometimes with evidence of prior infarction

Other imaging modalities

• CT scans may demonstrate associated bony involvement (e.g., osteosclerosis of the skull base) but are less sensitive than MRI for soft tissue lesions, which are the most common
• PET-CT can reveal systemic disease burden and help in monitoring treatment response, as CNS lesions may show increased FDG uptake⁶

Prognostic implications

Neurological involvement is consistently associated with poor survival in ECD. In one large cohort, patients with CNS disease had a median survival of 124 months compared to 146 months in patients without neurological complications.²

A systematic review reported an overall mortality of 33% among patients with CNS involvement, often due to complications like recurrent strokes, progressive ataxia, or severe endocrine dysfunction.⁴

Thus, recognising CNS involvement early is critical, not only for symptom control but also for improving long-term outcomes and survival.

Disease mechanisms & genetic basis

At the molecular level, CNS involvement in ECD appears linked to mutations in the MAPK pathway, especially the BRAF V600E mutation, which is present in over half of cases.⁷

This mutation drives abnormal histiocyte proliferation and infiltration of tissues, including the CNS. Identifying this mutation is important because it opens the door to targeted therapy with BRAF inhibitors such as vemurafenib.

Treatment considerations in CNS-involved ECD

Conventional therapies

Historically, treatment was limited to corticosteroids, interferon-α, or chemotherapy. These often provided only partial relief and limited impact on survival.⁶

Targeted therapies

With the discovery of the BRAF V600E mutation, targeted therapies have transformed outcomes.

• BRAF inhibitors (vemurafenib, dabrafenib) have shown remarkable efficacy. In one multicentre study, 43% of patients with neurological symptoms improved, and 45% showed radiological regression on MRI²
• MEK inhibitors (cobimetinib, trametinib) are effective in patients with other MAPK pathway mutations
• Combination therapy may be required in those with extensive or refractory CNS disease⁷

Supportive and symptom-directed care

• Surgery is rarely feasible but may be considered for decompression in cases of mass effect
• Physiotherapy and occupational therapy are essential for patients struggling with ataxia
• Endocrine replacement is needed in pituitary dysfunction

FAQs

How often does Erdheim-Chester disease affect the CNS?

CNS involvement occurs in around 40–50% of cases.^1,2

What symptoms should raise suspicion?

Ataxia, cranial neuropathies, vision changes, cognitive decline, or pituitary dysfunction (excessive thirst/urination from diabetes insipidus), although not always presenting.^4,6

What does an MRI show in CNS disease?

MRI can reveal tumoral lesions, white matter changes, or vascular involvement, often in the cortex, brainstem, cerebellum, or pituitary gland.³

Does CNS involvement worsen prognosis?

Yes. Patients with CNS lesions tend to have shorter survival and a mortality rate of around one-third.^2,4

Are there effective treatments?

Yes. Targeted therapies like BRAF and MEK inhibitors have improved both clinical symptoms and MRI findings in many patients.^2,7

Summary

• CNS involvement in ECD occurs in up to half of all patients and is a major contributor to morbidity and mortality
• Patients may present with cranial neuropathies, ataxia, seizures, or cognitive changes
• MRI is the investigation of choice, showing tumoral, pseudodegenerative, or vascular patterns
• CNS disease is associated with worse survival
• Advances in genetics have enabled targeted therapies that significantly improve symptoms and imaging findings